Zhejiang Int'l GroupLtd Valuation

Is 000411 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 000411 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 000411 (CN¥10.53) is trading below our estimate of fair value (CN¥71.64)

Significantly Below Fair Value: 000411 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 000411?

Key metric: As 000411 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 000411. This is calculated by dividing 000411's market cap by their current earnings.
What is 000411's PE Ratio?
PE Ratio	11.5x
Earnings	CN¥478.13m
Market Cap	CN¥5.71b

000411 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.3x
Enterprise Value/EBITDA	9.6x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 000411's PE Ratio compare to its peers?

The above table shows the PE ratio for 000411 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	32.6x
300194 Fuan Pharmaceutical (Group)	20.2x	n/a	CN¥6.0b
688513 Chengdu Easton Biopharmaceuticals	22.7x	23.5%	CN¥5.9b
301263 Guangdong Taienkang Pharmaceutical	42.9x	37.7%	CN¥6.0b
605199 Hainan Huluwa Pharmaceutical Group	44.8x	n/a	CN¥5.3b
000411 Zhejiang Int'l GroupLtd	11.5x	n/a	CN¥5.7b

Price-To-Earnings vs Peers: 000411 is good value based on its Price-To-Earnings Ratio (11.5x) compared to the peer average (32.6x).

Price to Earnings Ratio vs Industry

How does 000411's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 000411 is good value based on its Price-To-Earnings Ratio (11.5x) compared to the CN Pharmaceuticals industry average (31.1x).

Price to Earnings Ratio vs Fair Ratio

What is 000411's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

000411 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	11.5x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 000411's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥50.2b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥30.49

-2.1%

7.6%

China Resources Double-Crane PharmaceuticalLtd

CN¥22.7b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.80

-3.9%

12.1%

Dong-E-E-JiaoLtd

CN¥37.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥58.25

-1.7%

16.8%